Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän

Cerebral palsy and bruxis… - Göteborgs universitet Till startsida
Till innehåll Läs mer om hur kakor används på gu.se

Cerebral palsy and bruxism: Effects of botulinum toxin injections—A randomized controlled trial

Artikel i vetenskaplig tidskrift
Författare Birgitta Johansson Cahlin
Christopher Lindberg
Lars Dahlström
Publicerad i Clinical and Experimental Dental Research
Volym 5
Nummer/häfte 5
Sidor 460-468
ISSN 2057-4347
Publiceringsår 2019
Publicerad vid Institutionen för odontologi
Institutionen för neurovetenskap och fysiologi, sektionen för hälsa och rehabilitering
Institutionen för odontologi, sektion 1
Sidor 460-468
Språk en
Länkar dx.doi.org/10.1002/cre2.207
Ämnesord botulinum toxin, bruxism, cerebral palsy, oral physiology, oral rehabilitation, TMD
Ämneskategorier Odontologi


Objective: Cerebral palsy (CP) includes disturbances in muscular control caused by perinatal brain injury. Masticatory muscle involvement hampers functions such as chewing and talking. Bruxism and temporomandibular disorders are overrepresented. Neuromuscular blocks with botulinum toxin type A (BTX-A) may alleviate problems due to muscular hyperactivity. The aim was to evaluate masticatory muscle BTX-A injections in subjects with CP and bruxism. Methods: A prospective, parallel, randomized, placebo-controlled, and double-blind trial in 12 patients with CP was performed. End points were alterations in objective and subjective oral capacities after two BTX-A or corresponding placebo injections. Matched, healthy references were also evaluated. Results: The reference group demonstrated stronger and more efficient oral functions compared with the CP group. Subjective and objective oral capacities appeared to vary considerably between CP patients and also over time in this patient group and were poorly correlated. No significant effect of BTX-A compared with placebo on outcome variables was observed at group level, but continued treatment with BTX-A was requested by the majority of the patients. Conclusion: The evidence is unable to support the use of BTX-A for the treatment of affected masticatory muscles in CP, but the findings are inconclusive in certain respects. Larger, more homogeneous groups of CP patients need to be evaluated in future trials. ©2019 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?